



NDA 22-044

Merck & Co., Inc.
Attention: Steven A. Aurecchia, M.D.
Director, Regulatory Affairs
P.O. Box 1000, UG2CD-48
North Wales, PA 19454-1099

Dear Dr. Aurecchia:

Please refer to your new drug application (NDA) dated May 31, 2006, received May 31, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Janumet (sitagliptin/metformin hydrochloride) tablets, 50 mg sitagliptin/500 mg metformin HCl and 50 mg sitagliptin/1000 mg metformin HCl.

We acknowledge receipt of your submissions dated July 24, August 24, and October 19, 2006, and January 5, February 5 (2), and March 21 and 30, 2007.

This new drug application provides for the use of Janumet (sitagliptin/metformin hydrochloride) tablets as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the enclosed labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for package insert and text for the patient product information submitted on March 30, 2007, and immediate container and carton labels submitted on February 5, 2007). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an approved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 22-044.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for ages birth to 10 years, inclusive, and deferring pediatric studies for ages 11 to 16 years, inclusive, for this application.

Your deferred pediatric study required under section 2 of the Pediatric Research Equity Act (PREA) is considered a required postmarketing study commitment. The status of this postmarketing study shall be reported annually according to 21 CFR 314.81. This commitment is listed below.

1. Deferred pediatric study under PREA for the treatment of type 2 diabetes in pediatric patients ages 11 to 16, inclusive.

Protocol Submission:	by December 31, 2008
Study Start:	by March 31, 2009
Final Report Submission:	by September 30, 2011

Submit final study reports to this NDA. For administrative purposes, all submissions related to this pediatric postmarketing study commitment must be clearly designated “**Required Pediatric Study Commitment**”.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lina AlJuburi, Pharm.D., M.S., Regulatory Project Manager, at 301-796-1168.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, M.D.
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure: Package Insert, Patient Product Information, Container Labels, Carton Labels

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Mary Parks
3/30/2007 07:00:42 PM